The company can again ship the Duchenne gene therapy for patients who can still walk, following a one-week pause triggered by ...

Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to ...

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...

By nature, GenAI generates content probabilistically, meaning responses might vary slightly each time. But for life sciences ...

AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...

The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still ...

Leveraging a CDMO’s established platform for AAV manufacturing can significantly streamline gene therapy development.

The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of ...

The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...

Discover the latest breakthroughs in Alzheimer's research, diagnosis, and prevention in this expert-led podcast series.